













Cytotoxic Effects of Branched Cationic Peptides Derived from Bovine Lactoferricin on Oral Squamous Cell Carcinoma.





Diana A. Martinez-Baquero^{1*}, Paola A. Barato-Gomez², Sandra C. Vega-Chaparro¹ and Jaiver E. Rosas-Perez¹





Table S1. Characterization of synthetic peptides derived from bLFcin.





Sequence	RP-HPLC	MALDI-TOF MS
$^{17}\text{FKCRRWQWR}^{25}$		
$^{17}\text{FKCRRWQWRM}^{26}$		





Sequence	RP-HPLC	MALDI-TOF MS
$^{17}\text{FKCRRWQWRMK}^{27}$		
$^{17}\text{FKCRRWQWRMKK}^{28}$		

Sequence	RP-HPLC	MALDI-TOF MS
$^{17}\text{FKCRRWQWRMKKL}^{29}$		
$^{17}\text{FKCRRWQWRMKKLG}^{30}$		


Sequence	RP-HPLC	MALDI-TOF MS
¹⁷ FKCRRWQWRMKKLGA ³¹		
¹⁸ KCRRWQWRMKKLGA ³¹		

Sequence	RP-HPLC	MALDI-TOF MS
¹⁹ CRRWQWRMKKLGA ³¹	 RP-HPLC chromatogram showing a single sharp peak at 5.11 minutes. The y-axis is mAU (0 to 1800) and the x-axis is Minutes (0 to 10).	 MALDI-TOF MS spectrum showing a major peak at m/z 1718.008. The y-axis is Intens. [au] x 10⁴ (0.0 to 1.2) and the x-axis is m/z (1000 to 3500).
²⁰ RRWQWRMKKLGA ³¹	 RP-HPLC chromatogram showing a single sharp peak at 5.08 minutes. The y-axis is mAU (0 to 1000) and the x-axis is Minutes (0 to 10).	 MALDI-TOF MS spectrum showing a major peak at m/z 1617.38. The y-axis is Intens. [au] x 10⁴ (0.0 to 1.0) and the x-axis is m/z (1000 to 3500).

Sequence	RP-HPLC	MALDI-TOF MS
²⁰ RRWQWR ²⁵		
RWQWRWQWR		

Sequence	RP-HPLC	MALDI-TOF MS
(RRWQWR) ₂ KAhx		
(RRWQWR) ₂ KAhxC-		

A. Truncated C-termini bLFcin(17 - n)



B. Truncated N-termini bLFcin(n - 31)




Figure S1. Dose-response of linear peptides (**A.** truncated C-termini and **B.** truncated N-termini) against FaDu, SCC9 and HEK001 cells. Peptide concentrations tested = 100, 50, 25, 12.5, 6.25 μM. Cell viability determined by fluorescence detection of resazurin metabolic conversion to resofurin.



Tumor observation before bLFcin(20-25)₂ treatment



Tumor excised (right side) after 15-day treatment with bLFcin(20-25)₂



Tumor observation before saline treatment



Tumor excised (right side) after 15-day treatment with saline

Figure S2. Macrophotography of the tumors before and after treatment with bLFcin(20-25)₂ (top panel) and saline solution (bottom panel).




Figure S3. Weight of the animals in group A treated during weeks 14-15 with saline solution after macroscopically observation of tumors, and animals in group B treated during weeks 14-15 with 100 μM bLFcin(20-25)₂ after macroscopically observation of tumors.